Nivolumab,Ipilimumab
BMS
['biomarker', 'niche-2', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
great #esmo22 discussion re highly anticipated niche-2 study for colon cancer patient care. 15% of all stage crc is msi.
let's carve out who can avoid harm from chemo, benefit from i/o. then find biomarkers for early stage mss-ers who could also benefit. 
volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH